Ascendis Pharma A/S announced that as of December 16, 2024, they have closed a collaboration agreement with Novo Nordisk for developing products using their TransCon technology, which includes a potential $100 million milestone payment.
AI Assistant
ASCENDIS PHARMA A
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.